// App-Quantinova.ai

e21519 : Horizon: An ambispective study of 663 patients who initiated pembrolizumab for advanced melanoma within the French early access program.

Researchers

Presenter

  • Nicolas Meyer

Principal Investigators

  • Laurent Mortier

  • Caroline Dutriaux

  • Marie Therese Leccia

  • Brigitte Dreno

  • Evelyne Boos

  • Catherine Hunault

  • Lynda Benmahammed

  • Philippe Saiag

  • RIC-MEL

Medical Centers

  • Dermatology department, Institut Universitaire du Cancer de Toulouse et CHU de Toulouse, Toulouse, France

  • Dermatology Department, CHRU Lille, Lille, France

  • Dermatology and Pediatric dermatology department, Bordeaux hospital, Bordeaux, France, Bordeaux, France

  • Universite de Grenoble, Grenoble, France

  • Nantes University Hospital, Nantes, France

  • MSD France, Courbevoie, France

  • Dermatology department, CHU Ambroise Pare, AP-HP, Paris,, Boulogne-Billancourt, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • Unknown

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved